Nielk
Senior Member
- Messages
- 6,970
As Alex has been saying, we don't really have any direct say in what criteria get used in studies.
Apparently, we don't have any say about anything. Yet, most research for ME/CFS in the past 20 years has used the Fukuda criteria because that was the proposed research criteria that CDC produced. If any researcher wanted their research to mean anything, they used the Fukuda. Even now that a few researchers have started to use the CCC, it has been along with the Fukuda. If HHS states that the research criteria to be used from now on for the disease is the CCC, then that is what the researchers will use.
But I think it would be a huge mistake not to try and leverage the IOM report to get more funding for research. More funding means more studies and likely some or all will use CCC/ICC in isolation or in overlap with the IOM criteria. Even if some studies only used IOM criteria, more study increases the chance of finding a biomarker(s), which might well mean that the criteria issue becomes less important and/or clearer.
Studies using broad criteria like the IOM criteria will not be meaningful in my opinion. It will not help move the science forward and might give the wrong impression that biomarkers are not existent.